Chromatin Methylation Abnormalities in Autosomal Dominant Polycystic Kidney Disease

Area of Science:

• Nephrology
• Epigenetics
• Molecular Biology

Background:

• Autosomal dominant polycystic kidney disease (ADPKD) is a prevalent inherited kidney disorder and a leading cause of end-stage renal disease.
• The genetic basis of ADPKD primarily involves mutations in the *PKD1* and *PKD2* genes, but the precise pathogenic mechanisms remain incompletely understood.
• Epigenetic modifications, particularly chromatin methylation, are emerging as critical factors in ADPKD pathogenesis.

Purpose of the Study:

• To investigate the role of epigenetic modifications, specifically DNA, histone, and RNA methylation, in the development and progression of ADPKD.
• To identify potential diagnostic or prognostic biomarkers for ADPKD based on methylation patterns in body fluids.
• To explore the therapeutic potential of targeting epigenetic abnormalities in ADPKD.

Main Methods:

• Whole-genome bisulphite sequencing was employed to analyze DNA methylation patterns in ADPKD kidney tissues.
• Analysis of regional DNA methylation in accessible body fluids (blood and urine) was performed.
• The role of histone modifications and associated enzymes (histone methyltransferases) in ADPKD was considered.

Main Results:

• Extensive genome-wide hypomethylation was observed in ADPKD kidney tissues.
• Regional DNA methylation patterns in body fluids show promise as biomarkers for predicting ADPKD progression.
• Histone modifications contribute to aberrant methylation changes observed in ADPKD.

Conclusions:

• Epigenetic alterations, particularly aberrant DNA methylation, are integral to ADPKD.
• Methylation patterns in body fluids represent a viable avenue for developing diagnostic and prognostic tools for ADPKD.
• Targeting epigenetic dysregulation offers a promising strategy for future ADPKD therapeutic interventions.